Evaluation of Biofilm Formation and Antibiotic Resistance Pattern in Extended-Spectrum β-Lactamase-Producing Escherichia coli Strains

被引:10
|
作者
Jomehzadeh, Nabi [1 ]
Ahmadi, Khadijeh [1 ]
Nasiri, Zahra [1 ]
机构
[1] Abadan Univ Med Sci, Sch Med, Dept Microbiol, Abadan, Iran
来源
关键词
Biofilm; escherichia coli; extended-spectrum beta-lactamase; urinary tract infection; NONTUBERCULOUS MYCOBACTERIA; MOLECULAR CHARACTERIZATION; RISK-FACTORS;
D O I
10.4103/bbrj.bbrj_270_21
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: The increasing prevalence of multidrug-resistant (MDR) Escherichia coli strains, especially extended-spectrum beta-lactamase (ESBL)-producing strains, has become a global health concern. This study was aimed to determine the frequency of bla(CTX-M), bla(TEM), and bla(SHV) genes among E. coli isolates from urinary tract infection (UTI) and evaluate their antibiotic resistance pattern. Methods: Totally 98 E. coli isolates were recovered from urine samples of UTI-diagnosed patients. Antibiotic resistance and ESBL production were evaluated by disk diffusion and combined disk methods according to the Clinical Laboratory Standards Institute guidelines. The biofilm formation ability of isolates was assessed using the tube adherence method. ESBL-positive isolates were screened for bla(TEM), bla(CTX-M), and bla(SHV) genes by polymerase chain reaction. Results: Among the examined isolates, 25 (25.5%) were detected as ESBL producers and harbored at least one of the studied genes. The bla(CTX-M) was the predominant (44%) gene, followed by bla(TEM) (24%) and bla(SHV) (8%). The isolates revealed variable resistance levels to all antimicrobials, out of which 55.1% were conferred a high resistance rate to different antibiotic classes and considered MDR. Phenotypically, 42.85% of the isolates were biofilm formers, of which the majority (38%) formed moderate biofilms. Conclusions: This study showed that the ESBL-positive isolates were more resistant to some first-line antibiotics, and this highlights the necessity to control and monitor the prescribed antibiotics used for empirical treatment for UTI patients.
引用
收藏
页码:175 / 179
页数:5
相关论文
共 50 条
  • [31] Oral Antibiotic Transition in Patients with Bacteremia with a Urinary Source Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli
    Noguchi, Taro
    Shinohara, Koh
    Tsuchido, Yasuhiro
    Yukawa, Satomi
    Yamamoto, Masaki
    Matsumura, Yasufumi
    Hayashi, Michiko
    Yamada, Yutaka
    Hayashi, Akihiko
    Shimizu, Tsunehiro
    Nagao, Miki
    JAPANESE JOURNAL OF INFECTIOUS DISEASES, 2022, 75 (02) : 205 - 208
  • [32] Population snapshot of the extended-spectrum β-lactamase-producing Escherichia coli invasive strains isolated from a Hungarian hospital
    Toth, Kinga
    Toth, Akos
    Kamotsay, Katalin
    Nemeth, Viktoria
    Szabo, Dora
    ANNALS OF CLINICAL MICROBIOLOGY AND ANTIMICROBIALS, 2022, 21 (01)
  • [33] The first identification of an extended-spectrum β-lactamase-producing Escherichia coli from Norwegian livestock
    Sunde, M.
    Tharaldsen, H.
    Solheim, H.
    Norstroem, M.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S272 - S272
  • [34] Faecal carriage of extended-spectrum β-lactamase-producing Escherichia coli in a remote region of Niger
    Jacquier, Herve
    Assao, Bachir
    Chau, Francoise
    Guindo, Ousmane
    Condamine, Benedicte
    Magnan, Melanie
    Bridier-Nahmias, Antoine
    Sayingoza-Makombe, Nathan
    Moumouni, Aissatou
    Page, Anne-Laure
    Langendorf, Celine
    Coldiron, Matthew E.
    Denamur, Erick
    de Lastours, Victoire
    JOURNAL OF INFECTION, 2023, 87 (03) : 199 - 209
  • [35] Prospective Validation of Cessation of Contact Precautions for Extended-Spectrum β-Lactamase-Producing Escherichia coli
    Tschudin-Sutter, Sarah
    Frei, Reno
    Schwahn, Friedbert
    Tomic, Milanka
    Conzelmann, Martin
    Stranden, Anne
    Widmer, Andreas F.
    EMERGING INFECTIOUS DISEASES, 2016, 22 (06) : 1094 - 1097
  • [36] RISK FACTORS FOR EXTENDED-SPECTRUM β-LACTAMASE-PRODUCING ESCHERICHIA COLI INFECTION IN HOSPITALIZED PATIENTS
    Ikeda, Yoshiaki
    Mamiya, Takayoshi
    Nishiyama, Hideki
    Koseki, Takenao
    Mouri, Akihiro
    Nabeshima, Toshitaka
    NAGOYA JOURNAL OF MEDICAL SCIENCE, 2012, 74 (1-2): : 105 - 114
  • [37] Risk Factors for Bloodstream Infections due to Extended-spectrum β-lactamase-producing Escherichia coli
    Wu, Un-In
    Yang, Ching-Shiang
    Chen, Wan-Chin
    Chen, Yee-Chun
    Chang, Shan-Chwen
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2010, 43 (04) : 310 - 316
  • [38] Polyclonal distribution of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Stockholm
    Titelman, E.
    Iversen, A.
    Lagergren, A.
    Kuhn, I.
    Kahlmeter, G.
    Giske, C.
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2007, 29 : S90 - S91
  • [39] Comparison of the MICs of cefepime for extended-spectrum β-lactamase-producing and non-extended-spectrum β-lactamase-producing strains of Enterobacter cloacae
    Gottlieb, T
    Wolfson, C
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 46 (02) : 330 - 332
  • [40] Extended-spectrum β-lactamase-producing organisms
    Falagas, M. E.
    Karageorgopoulos, D. E.
    JOURNAL OF HOSPITAL INFECTION, 2009, 73 (04) : 345 - 354